Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 24 2018 - 8:30AM
Hemispherx Biopharma, Inc. (NYSE American: HEB) an
immuno-pharma R&D and emerging commercial growth company
focused on unmet medical needs in immunology, announced today that
it will be presenting at the 20th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held on September 4-6, 2018
at the St. Regis New York Hotel in New York City.
Thomas K. Equels, M.S. J.D., chief executive officer of
Hemispherx, will be presenting and meeting one-on-one with
investors. Mr. Equels' presentation will focus on immuno-oncology,
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and
immune system amplification for enhanced viral vaccines. Mr. Equels
will also discuss how the Company is working with several major
cancer research centers to initiate Phase 1 and Phase 2 clinical
trials combining Ampligen with FDA-approved checkpoint blockade
therapies in several different and highly lethal solid tumors.
The presentation will be webcast live. To access the
webcast, please visit www.rodmanevents.com. The webcast
replay will remain available for 90 days following the live
presentation at
http://wsw.com/webcast/rrshq28/heb/.
Hemispherx has two flagship products: Ampligen® approved in
Argentina with a NDA pending in the United States and Alferon N
Injection® approved in the United States and Argentina. Ampligen®
has the potential to address multiple indications, including
various cancers, ME/CFS and influenza. Alferon N Injection® also
has multiple potential indications, including MERS and as a
component of an immune modulating cocktail designed to favorably
improved the microenvironment of several solid tumors. The
Company also has six orphan drug designations, with four in the
United States and two in the European Union. Their combined
estimated market is estimated in the billions of dollars.
About Hemispherx Biopharma Hemispherx
Biopharma, Inc. is an immuno-pharma R&D and emerging commercial
growth company focused on unmet medical needs in immunology.
Hemispherx’s flagship products include Alferon N Injection® and the
experimental therapeutic rintatolimod (tradenames Ampligen® or
Rintamod®). Rintatolimod is an experimental RNA nucleic acid being
developed for globally important debilitating diseases and
disorders of the immune system, including immuno-oncology and
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Hemispherx’s platform technology includes components for potential
treatment of various severely debilitating and life-threatening
diseases. Because rintatolimod is experimental in nature, it is not
designated safe and effective by the FDA for general use and is
legally available only through clinical trials.
Cautionary StatementSome of the statements
included in this press release may be forward-looking statements
that involve a number of risks and uncertainties. Among other
things, for those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements set forth in this press release speak only as of the
date of this press release. We do not undertake to update any of
these forward-looking statements to reflect events or circumstances
that occur after the date hereof. This press release and prior
releases are available at www.hemispherx.net. The information found
on our website is not incorporated by reference into this press
release and is included for reference purposes only.
ContactHemispherx Biopharma, Inc. Phone Number:
800-778-4042 Email: IR@hemispherx.net
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2023 to Apr 2024